The molecular detection for Candida guilliermondii (Meyerozyma guilliermondii) is used for the immediate, with high specificity and sensitivity laboratory diagnosis of the fungus (yeast) in various biological materials. Molecular testing for Candida guilliermondii (Meyerozyma guilliermondii) is included in the 14 different species of Yeast-like Fungi, Molecular Detection MycoScreen™.
Candida guilliermondii is an uncommon species of Candida that is most often associated with onychomycosis and is rarely seen as a cause of invasive fungal infection.
Reports suggest that although rare, C. guilliermondii may exhibit decreased susceptibility to several different classes of antifungal agents, may be transmitted from patient to patient in the hospital setting, and may be associated with the presence of an intravascular foreign body. Recent in vitro survey data confirm the decreased susceptibility of this species to fluconazole.
Aside from limited observations, there is little information regarding the epidemiology, frequency of occurrence, and antifungal susceptibility profile of this rare species of Candida. Given the fact that the data available suggest the potential for decreased susceptibility of C. guilliermondii to polyenes, azoles, flucytosine, and echinocandins, it seems prudent to gather additional information regarding this opportunistic fungal pathogen.
Candida guilliermondii is widely distributed in nature (routinely isolated from insects, soil, plants, atmosphere, seawater, the exudates of various trees, and processed foods) and is a common constituent of the normal human microflora. Globally, this species accounts for 1 to 2% of all candidemia cases.
Candida guilliermondii characteristics
- A causative agent of onychomycosis
- A causative agent of invasive candidiasis in patients with neoplastic diseases (hematological diseases, solid tumors, and neutropenia), and in patients after cardiovascular or intra-abdominal operations
- May cause catheter-associated candidemia
- May cause candidal osteomyelitis